Reach Us +1-217-403-9671
Development Of Antibody Arrays For Measuring Biosimilar Conformational Comparability At Molecular Level | 8146
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Development of antibody arrays for measuring biosimilar conformational comparability at molecular level

International Conference and Exhibition on Biowaivers & Biosimilars

Xing Wang

Posters: J Bioequiv Availab

DOI: 10.4172/0975-0851.S1.007

For Biosimilar development, the three dimensional structure of the molecule is closely related to its efficacy and safety including immunogenicity. Recent guidelines from FDA on Biosimilars gave specific instructions on the analysis of protein tertiary structure. This presentation described a new approach to measure biosimilar molecule conformational changes systematically and at molecular level. A large number of different antibodies were developed toward a single biosimilar molecule to cover the whole protein sequence, and interrogate its conformational changes and compare the information with that of the innovator molecule. Case studies will be presented to demonstrate that this sensitive and robust technology can be applied to biosimilar cell line selection, process and formulation development, and many other aspects of biosimilar drug development.
Xing Wang, Ph.D. is President of Array Bridge Inc. since 2011. Before establishing Array Bridge Inc., Xing worked at Pfizer for 15 years and was a Group Leader and Associate Research Fellow. His experience includes small molecule and protein therapeutics drug discovery and development, successful application of proteomics, genomics and bioinformatics to target identification and validation in the small molecule drug discovery. For the past 8 years, his focus is on the development of protein therapeutics, building platforms for the identification and characterization of process-related impurities such as host cell proteins (HCPs) and residual DNA (rDNA). Xing has more than 30 publications including many in biologics development
Relevant Topics